Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance bevacizumab with or without metronomic chemotherapy after induction FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
2011-006332-23Phase 2Active
- Sponsor
- Arco Therapeutics
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, capecitabine, cyclophosphamide, fluorouracil, oxaliplatin and 2 more in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Arco Therapeutics. Primary endpoint: Progression-free survival. Started Apr 2012; status: active.
02
Drugs
bevacizumabcapecitabinecyclophosphamidefluorouraciloxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-006332-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006332-23.